Table 5 Novel agents in MZLs Agent .... | American Society of Hematology

Table 5

Novel agents in MZLs

Agent	Year	Phase	Patient status	No. of patients	MZL	Response
Agent	Year	Phase	Patient status	No. of patients	MZL	ORR	Duration
Vorinostat¹⁰⁴	2011	1	RR	35	9	22%	Median PFS 18.8 mo
Ibrutinib¹⁰⁵	2013	1	RR	56	4	25%	NR
Idelalisib¹⁰⁶	2014*	2	RR	125	15	47%	Median PFS 6.6 mo Median DOR 18.4 mo
Lenalidomide + Rituximab¹⁰⁷	2014	2	First line	103	27	89%	Median PFS 53.8 mo

Agent	Year	Phase	Patient status	No. of patients	MZL	Response
Agent	Year	Phase	Patient status	No. of patients	MZL	ORR	Duration
Vorinostat¹⁰⁴	2011	1	RR	35	9	22%	Median PFS 18.8 mo
Ibrutinib¹⁰⁵	2013	1	RR	56	4	25%	NR
Idelalisib¹⁰⁶	2014*	2	RR	125	15	47%	Median PFS 6.6 mo Median DOR 18.4 mo
Lenalidomide + Rituximab¹⁰⁷	2014	2	First line	103	27	89%	Median PFS 53.8 mo

Updated at the 56th American Society of Hematology Annual Meeting and Exposition, San Francisco, CA, December 6-9, 2014.